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Carcinogenesis is an evolutionary process that establishes the ‘hallmarks of cancer’ by natural selection of cell clones that have
acquired advantageous heritable characteristics. Evolutionary adaptation has also been proposed as a mechanism that promotes drug
resistance during systemic cancer therapy. This review summarises the evidence for the evolution of resistance to cytotoxic and
targeted anti-cancer drugs according to Darwinian models and highlights the roles of genomic instability and high intra-tumour genetic
heterogeneity as major accelerators of this evolutionary process. Clinical implications and strategies that may prevent the evolution of
resistance or target the origins of genetic heterogeneity are discussed. New technologies to measure intra-tumour heterogeneity and
translational research on serial biopsies of cancer lesions during and after therapeutic intervention are identified as key areas to further
the understanding of determinants and mechanisms of the evolution of drug resistance.
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‘It may be said that natural selection is daily and hourly
scrutinising, throughout the world, every variation, even the
slightest; rejecting that which is bad, preserving and adding up
all that is good; silently and insensibly working, wherever
and whenever opportunity offers, at the improvement of each
organic being in relation to its organic and inorganic
conditions of life.’
Charles Darwin—On the Origin of Species by Means of Natural
Selection, 1859
Charles Darwin proposed that natural selection is the mechanism
that leads to evolutionary change of species over time. Cancer was
first described as an evolutionary process by Nowell (Nowell,
1976), who hypothesised that natural selection occurs in tumours
in the form of clonal selection leading to constant evolutionary
change and possibly to drug resistance. Evolutionary processes in
cancer development and progression have since been studied,
which has allowed remarkable insights into the biology of cancer
(for summary, see Graves, 2000). In contrast, our understanding of
the contribution of evolutionary processes to the development
of drug resistance is still in its infancy and, with the major
exception of Goldie and Coldman’s principles to prevent the
evolution of drug resistance through the of use combination
chemotherapy at the earliest possible time (Goldie and Coldman,
1984), what is known has hardly translated into clinical strategies
to improve the outcome of cancer therapy. This review sum-
marises current evidence for the role of Darwinian evolution of
tumours during drug treatment and derives clinical strategies that
may help to elucidate this process in detail and ultimately prevent
tumour acquisition of drug resistance.
EVOLUTIONARY GROUND RULES
Three prerequisites are necessary and sufficient for evolution
by natural selection to occur:
(i) Individual variations exist in the population
(ii) These variations are heritable
(iii) Variations in individuals lead to differential survival and
reproduction
Evolution by natural selection is the causal consequence because
individuals with favourable characteristics are positively selected
based on their reproductive advantage, whereas less well-adapted
individuals are eliminated from the population through negative
selection. On the basis of these principles, the main determinant of
the ability of a population to evolve is the extent of heritable
variation within the population.
TUMOUR SOMATIC MUTATIONS AND GENETIC
INTRA-TUMOUR HETEROGENEITY
Cancer is caused by DNA and epigenetic alterations and usually
arises as a clonal growth from a single founder cell (Fialkow, 1979).
Insights into the frequency and pattern of somatic mutations
across whole cancer genomes became available recently through
the advent of next-generation sequencing technology. For example,
sequencing of all protein coding genes in several solid tumours,
including glioblastomas, colorectal, pancreatic and breast cancers,
revealed approximately 40–80 mutations per tumour, which alter
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www.bjcancer.comprotein sequence (reviewed in Fox et al, 2009). Importantly, the
sequencing techniques applied in these studies were not optimised
to detect mutations that were only present in a small fraction of
tumour cells within the sequenced samples. By the time a cancer
reaches detection limits, it is composed of billions of malignant
cells, all carrying somatic mutations that were present in the
founder cell but also additional mutations acquired by generations
of daughter cells during tumour progression, which were passed
on to their individual clonal progeny. Thus, although most cancers
are of monoclonal origin, the expansion of the population size,
which occurs after malignant transformation, coupled with the
constant acquisition of mutations promotes the diversion into
subclones and a dramatic increase in genetic tumour heterogeneity
(Figure 1). Somatic mutation analyses of the immunoglobulin
heavy gene locus by ultra-deep sequencing in chronic lymphocytic
leukaemia detected multiple subclones in most samples, which
supports this model (Campbell et al, 2008). Phylogenetic trees
constructed from these data furthermore demonstrated ancestral
relationships of subclones and provided evidence for Darwinian
evolution by positive selection. Genetic heterogeneity has also been
detected in many solid tumours ( Marusyk and Polyak, 2010) but is
probably significantly under-reported in cancer genome sequen-
cing studies because they overlooked rare mutations. Thus, robust
data regarding the total number of mutations and subclones in
clinically detectable tumours are unavailable but current estimates
are as high as several billions (Klein, 2006). As Darwinian
evolution is fuelled by this population heterogeneity, the study
of the origin and measurements of the extent of genetic
heterogeneity are key steps to understand how cancer drug
resistance develops. A further obstacle for the interpretation of
large-scale somatic mutation analyses is that fitness effects of the
vast majority of mutations are unknown. The RNA interference-
based functional genomic screening approaches can experimen-
tally test the phenotypic effect of silencing large numbers of genes
individually and may support the interpretation of mutation
data sets by identifying genes that influence cellular fitness or drug
sensitivity.
GENOMIC INSTABILITY: FOUNDATIONS FOR
GENETIC HETEROGENEITY IN CANCER?
On the basis of the multistep model of carcinogenesis, several
mutations need to accumulate for a cancer to arise. Loeb (1991)
showed by mathematical modelling that a colorectal cancer with
such moderately large numbers of mutations cannot arise within
the lifetime of a human under the assumption that mutation rates
are similar to those observed in normal tissues. He proposed
that cells need to adopt a mutator phenotype, which leads to an
elevated rate at which genomes acquire changes, at an early stage
of carcinogenesis to acquire the number of mutations necessary
for malignant transformation. His results were challenged by
Tomlinson et al (1996), who showed that the natural mutation rate
is sufficient for carcinogenesis with the proviso that some of these
mutations provide a fitness advantage leading to the clonal
expansion of a large enough target population to produce the
necessary subsequent mutations. The discussion as to whether
the natural mutation rate is sufficient to generate the number
of mutations observed in advanced cancers or whether genomic
instability is mandatory, is still ongoing. Regardless of whether
genomic instability is a necessity for carcinogenesis, it has been
identified in many advanced tumours and leads to increased
genetic intra-tumour heterogeneity (Lengauer et al, 1998).
Furthermore, accelerated evolutionary adaptation through geno-
mic instability has been shown by studies linking chromosomal
instability (CIN), genomic instability characterised by frequent
losses or gains of chromosomes during cell divisions, with the
accelerated acquisition of drug resistance phenotypes of cancer
cells in vitro (Duesberg et al, 2000) and with early tumour
recurrence after drug treatment in animal models (Sotillo et al,
2010). The clinically important concept that increased hetero-
geneity could accelerate evolutionary adaptation and possibly
enhance biological fitness to counter environmental selection
pressures could in turn favour the clonal selection of genomically
unstable cancer cells by cancer therapies. These potential
advantages conferred by genomic instability to the tumour cells
must be balanced against the selective disadvantage, which can
result from the generation of large numbers of cells with
deleterious mutations or tumour lethality conferred by excessive
chromosomal instability in animal models (Weaver et al, 2007).
Importantly, evolutionary models have revealed that genomic
instability can be positively selected on the basis of its proliferation
advantage in environments with high DNA damage rates
(e.g. during chemotherapy) in which unstable cells avoid cell
cycle arrest after DNA damage in contrast to genomically stable
cells that are negatively selected because they frequently undergo
cell cycle arrest and have a lower proliferation rate (Komarova and
Wodarz, 2003).
Thus, it is conceivable that there is an optimal degree of genome
instability required to accelerate the development and progression
of cancers and that excessive instability is deleterious to the
tumour. Results from animal tumour models demonstrating that
excessive chromosomal instability may have a tumour-suppressive
role leads to the tantalising proposal that exacerbation of tumour
genome instability provides an opportunity for therapeutic
intervention (Weaver et al, 2007).
EVIDENCE FOR DRUG RESISTANCE BY DARWINIAN
EVOLUTION
The harsh clinical reality is that acquired multi-drug resistance
almost invariably occurs in advanced and metastatic solid tumours
leading to disease progression and eventually death. The following
examples highlight how Darwinian evolution driven by intra-
tumoural genetic heterogeneity fosters resistance to the selection
pressure of systemic cancer therapies. This analysis of drug
resistance from a Darwinian perspective should allow better
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Figure 1 Schematic view of tumour heterogeneity during tumour
progression and treatment. Acquired mutations in daughter cells of a single
founder cell (left) promote diversion into subclones (different colours
reflect different clones). Some new mutations lead to accelerated growth
(for example yellow and orange clones). Fitness reducing mutations lead
to negative selection (cells with brown cytoplasm). Drug treatment leads to
selective survival of a drug resistant clone (pink) and generates an
evolutionary bottleneck that reduces genetic heterogeneity transiently.
Heterogeneity is re-established rapidly through acquisition of mutations
by daughter cells of the resistant clone.
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strategies to limit tumour acquisition of drug resistance.
Selection conferred by cytotoxic chemotherapy
Inactivating mutations of the MSH6 mismatch repair gene were
identified in a sequencing study of recurrent glioblastoma multi-
forme after treatment with the alkylating agent temozolomide
but not in untreated tumours (Hunter et al, 2006). Such muta-
tions confer temozolomide resistance, probably by preventing
temozolomide-induced cell death (Yip et al, 2009) and cause a
hypermutator phenotype as evidenced by the detection of
approximately 200000 somatic point mutations in MSH6-mutant
tumours after temozolomide treatment. The ability to detect this
mutational pattern by DNA-sequencing approaches mandates their
presence in the majority of cells in the analysed sample. This
implies that temozolomide chemotherapy led to positive selection
of MSH6-mutant cells and elimination of the majority of daughter
clones present in the pre-treatment tumour. This clonal selection
of MSH6-mutant cells would be predicted to lead to a transient but
dramatic reduction in tumour heterogeneity before the expansion
of the resistant clone re-establishes genetic heterogeneity through
the acquisition of new mutations (Figure 1). Such an evolutionary
bottleneck (Merlo et al, 2006) may provide a therapeutic window
of opportunity to target the emerging resistant clone, whereas
genetic heterogeneity and hence the potential for drug resistance to
evolve is low. The hypermutator state induced by the MSH6
mutation is of great clinical concern as it may facilitate rapid
evolution of clones with higher fitness, and thereby contribute
to tumour progression and resistance to subsequent lines of
treatment.
Inactivating BRCA2 mutations impair the error-free cellular
double-strand DNA repair system and carriers of germ line BRCA2
mutations are predisposed to the development of breast, ovarian
and other cancers (Rahman and Stratton, 1998). Such cancers are
highly sensitive to drugs that induce double-strand breaks such as
the DNA-damaging platinum agents and PARP inhibitors that
block a complementary DNA repair pathway (Fong et al, 2009).
Thus, inactivating BRCA2 mutations cause genomic instability
that promotes carcinogenesis but also increase the sensitivity to
specific drugs. Secondary mutations of the mutant BRCA2 gene,
which restore BRCA2 function and lead to PARP inhibitor
resistance have been identified in BRCA2-defective cell lines after
they acquired resistance to these drugs (Edwards et al, 2008). The
reversal of BRCA2-inactivating point mutations occurred by short
deletions that are potentially fostered by BRCA2 dysfunction itself.
This may highlight that the increased genetic plasticity induced
by genomic instability accelerates the evolution of resistance in
these cases.
The rapid acquisition of tumours to non-cross resistant
cytotoxics, which the tumour has not yet been exposed to, is a
major cause of treatment failure in patients who relapse after
chemotherapy (Gottesman et al, 2002). The selection of a single
sub-clone harbouring a mutation that confers resistance specifi-
cally to the challenging chemotherapy drug does not sufficiently
explain how cross-resistance to structurally and mechanistically
unrelated drugs arises. Several mechanisms including the expres-
sion of multidrug efflux pumps, degree of apoptosis proficiency,
and increased activity of drug detoxification mechanisms have
been identified as potential mechanism of multidrug resistance
(reviewed in Gottesman et al, 2002). Genomic instability is also
likely to have a vital role in this process by increasing genetic
intra-tumour heterogeneity and fostering the simultaneous
presence of multiple drug-resistant clones or the provision of
means through which these clones can be developed. The frequent
losses and gains of whole chromosomes during cell divisions in
CIN cancer cells trigger rapid alterations in gene dosage (Duesberg
et al, 2000). In vitro studies have confirmed that CIN cells acquire
multi-drug resistance at an accelerated rate compared with diploid
cells resulting from the selection pressure influenced by drug
exposure that is likely to be ‘catalysed’ by whole chromosome mis-
segregation events (Duesberg et al, 2000). Clinical evidence
substantiating a role for chromosomal instability in driving
multi-drug resistance is still limited, principally because methods
to detect differences in tumour karyotype from cell to cell are
poorly developed and not suitable to high throughput approaches.
However, an RNA expression signature reflecting chromosomal
instability has been shown to be associated with poor prognosis in
six different cancer types (Carter et al, 2006) and with taxane
resistance in ovarian cancers (Swanton, 2009), supporting the
hypothesis that CIN is associated with poor prognosis and
resistance to therapy. In contrast, CIN ovarian cancers seem to
be more likely to respond to platinum agents, indicating that this
tumour-specific phenotype might be targetable. The reason for this
increased sensitivity is unclear but the inability to tolerate
excessive DNA damage analogous to the effect of PARP inhibitors
on BRCA mutation carriers (Fong et al, 2009) is a possibility.
Therefore, genomic instability phenotypes, exemplified by CIN,
increase the likelihood of drug-specific and multidrug resistance
mechanisms occurring simultaneously, or as has been suggested
‘a selected phenotype’, namely drug-specific resistance catalysed
by a putative gene or gene on a mis-segregated chromosome, is
associated with ‘multiple unselected phenotypes’ or multi-drug
resistance, conferred by dramatic alterations in gene dosage
brought about by the selected whole chromosome mis-segregation
event (Duesberg et al, 2000).
Selection conferred by targeted drugs
The BCR–ABL translocation is the characteristic driver mutation
in chronic myeloid leukaemia (CML). Targeted treatment with the
BCR–ABL inhibitor imatinib leads to complete cytogenetic
remissions in a high proportion of patients. The emergence of a
subclone of leukaemic cells carrying an imatinib resistance
mutation in the BCR–ABL kinase domain is the main cause
of relapse in patients treated with imatinib (Gorre et al, 2001).
The BCR–ABL mutations T315I and E255K, which both confer
imatinib resistance, have been shown to pre-exist in minority sub-
populations of CML cells from many treatment naive patients and
can be detected by sensitive PCR-based methods (Roche-Lestienne
et al, 2002). Both mutations have a higher leukaemogenic potential
than the non-mutated BCR–ABL clones. Alternative resistance
mutations (Y253H, M351T, F317L and T315A) with a lower
leukaemogenic potential than the unmutated BCR–ABL gene have
also been identified in imatinib-resistant CML (Skaggs et al, 2006).
Thus, the selection of a resistant clone by cancer treatment can
influence disease biology and potentially clinical behaviour by
selecting for more or less aggressive clones. Nilotinib and dasatinib
are second generation BCR–ABL inhibitors specifically designed
to retain activity against most imatinib-resistant BCR–ABL
mutants (Druker, 2006). Whether such drugs can delay the
occurrence of resistance when used in the first line setting by
preemptively targeting the resistance mechanism that will most
likely evolve is currently being investigated in clinical trials. If this
strategy is successful, similarly designed second-generation
targeted drugs that inhibit the primary driver mutation but also
potential resistance mutations may improve the outcomes of many
other cancer types with known targetable pathways. However,
several co-existing CML clones carrying different imatinib
resistance mutations were identified in a number of patients
before treatment who subsequently developed resistance to
imatinib (Shah et al, 2002). The occurrence of polyclonal
resistance in genetically heterogeneous tumour cell populations
is of clinical importance because a single drug may be insufficient
to target all resistant BCR–ABL variants. This demonstrates the
need to develop specific drugs for various resistance mutations
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resistance clones present in the pre-treatment tumour or emerging
during treatment.
The EGF receptor tyrosine kinase inhibitor (TKI) gefitinib has
high activity in patients with non-small cell lung cancers that
harbour activating somatic mutations of the EGF receptor (Lynch
et al, 2004). In contrast, the secondary EGFR mutation T790M
causes insensitivity to gefitinib and is detectable in 50% of patients
after the acquisition of drug resistance (Kosaka et al, 2006).
Analogous to the pre-existence of imatinib resistance mutations in
some treatment-naive CML patients, the presence of the T790M
mutation was also detected in a minority population of cancer cells
in some TKI-naive patients who subsequently develop resistance
(Inukai et al, 2006). The presence of resistance mutations before
treatment initiation is associated with a significantly shorter
response duration and the prevalence of the T790M allele in CTCs
has been shown to increase over time during gefitinib treatment,
which provides direct evidence for clonal expansion of resistant
clones on treatment (Maheswaran et al, 2008). The detection of
changes in clonal composition by CTC analyses during drug
therapy further demonstrate that real-time tumour genotyping is
possible with this technique. Surprisingly, this study also detected
the emergence of distinct EGFR-activating mutations from CTCs,
which were different from the activating EGFR mutations present
in the primary tumours. This is a further example of how drug
treatment can shape tumour biology by negatively selecting the
initially dominant clone and promoting selection of a resistant
clone with a distinct driver mutation.
Darwinian evolution of drug resistance: complexities
and limitations
These examples demonstrate the applicability of Darwinian
concepts to the development of cancer cell intrinsic drug resistance
phenotypes. However, Darwinian evolution results from the
complex interactions of heritable phenotypes with multiple
environmental and microenvironmental influences that need to be
considered in the drug resistance process. For example, the selection
pressure resulting from imatinib treatment in CML is modulated by
microenvironmental influences as exemplified by studies in CML
mouse models that demonstrate that cytokine secretion from the
tumour stroma can precipitate imatinib resistance (Williams et al,
2007). Furthermore, re-modelling of the microenvironment through
recruitment of bone marrow-derived cells, including macrophages
and suppressor cells can establish resistance to anti-angiogenic
agents (Shojaei and Ferrara, 2008). It remains unclear whether the
acquisition of mutations in cancer cells or co-evolving mutations or
epigenetic modification of stromal cells control such microenviron-
mental changes conferring drug resistance. The current intense
study of cancer cell–stroma interactions will undoubtedly provide
further insights into these processes.
Furthermore, non-mutational drug resistance mechanisms, illu-
strated by the survival of naturally treatment resistant cancer stem
cells or quiescent cells that are protected from the effects of
chemotherapy drugs that target rapidly proliferating cells, are likely
to contribute to therapeutic failure and require further intense study.
Finally, CML and non-small cell lung cancers with activating
EGF receptor mutations may be exceptional examples due to their
dependence on a single driver mutation that can be targeted
directly by tyrosine kinase inhibitors. Nonetheless, the discovery of
a minority population of cells in newly diagnosed patients with
acute lymphoblastic leukaemia, which corresponds to the relapse
clone emerging after chemotherapy indicates that pre-existent
drug-resistant clones are also relevant for the development of
resistance to classic cytotoxic chemotherapy regimens (Mullighan
et al, 2008). Further research is necessary to define if Darwinian
concepts of drug resistance can be applied to all tumour entities
and cancer drugs.
STRATEGIES BASED ON EVOLUTIONARY THEORY
Comprehensive sampling techniques and measuring
heterogeneity
Single biopsies are likely to be sub-optimal to provide detailed
information about the global genomics of heterogeneous tumours.
New tumour-sampling techniques, CTC collection or the analysis
of circulating tumour DNA, may allow a more comprehensive
analysis of the clonal composition of a cancer provided that
cancer cells are shed into the circulation proportional to their
clonal frequency. These are areas that require further research.
Technologies that can detect pre-existing resistance mutations
in heterogeneous tumours before treatment initiation may allow
individualised drug therapy approaches avoiding the rapid
selection of existing resistant clones. Tools to measure and
characterise the genetic heterogeneity of tumours and to detect
and quantify genomic instability are also poorly developed, which
precludes establishing the exact contribution of these phenomena
to accelerated tumour progression and the development of drug
resistance. The development of technologies to address these
issues should be given high priority to improve the currently
predominant monoclonal model of advanced cancers with a more
realistic model incorporating genetic heterogeneity.
Monitoring dynamic changes of clonal composition
to guide drug therapy
Monitoring changes in clonal composition during cancer drug
treatment is crucial to further the understanding of the Darwinian
evolution of drug resistance. Techniques to perform serial biopsies
of tumours and to analyse CTCs or circulating tumour DNA during
drug therapy should be further developed for these purposes. This
may provide direct evidence of positive and negative clonal
selection and the detection of emerging clones carrying drug-
resistance mutations may allow early modification of treatment
strategies before clinical progression occurs. The adjustment of the
therapeutic strategy based on the resistance profile of residual
cancer cells after induction treatment has significantly decimated
the population size and with it genomic heterogeneity, may also
prevent or delay the development of resistance.
Therapeutic strategies exploiting clonal competition
Evolutionary modelling approaches led to the proposal of a new
therapeutic strategy that aims to maintain a stable tumour
population instead of trying to achieve maximal cell kill (Gatenby
et al, 2009). This prevents the elimination of sensitive tumour
clones which should, in theory, suppress the growth of therapy
resistant clones in a competitive manner. A basic assumption of
this strategy is that resistant clones have a lower fitness than
sensitive clones because they commit more resources to maintain
the resistant phenotype. This strategy has been tested in animal
models of ovarian cancer treated with carboplatin but proof of
principle in humans is not yet available.
Exploiting genomic instability
Intra-tumour genetic heterogeneity fosters the development of
cancer drug resistance by Darwinian evolution and genomic
instability mechanisms contribute to such heterogeneity in many
tumour types. Thus, genomic heterogeneity may be an attractive
therapeutic target to prevent evolution of more aggressive or
resistant clones. Synthetic lethality approaches, as exemplified by
the use of PARP inhibitors in BRCA-mutant cancers, can specifically
target genomically unstable cancer cells by increasing instability to
intolerable levels. Similar approaches should be explored to target
CIN and other cancer-associated forms of genomic instability.
Darwinian evolution of drug resistance
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such as CIN in vivo are still largely unknown and further research to
identify genes that promote or sustain CIN should be given high
priority to support such developments.
CONCLUSION
Darwinian evolution contributes to clinical resistance to tradi-
tional chemotherapy and targeted drugs. A main driver of
evolutionary adaptation during drug treatment is the genetic
heterogeneity present in clinically detectable tumours, which is
itself determined by population size and fostered by genomic
instability. New tools are necessary to study heterogeneity and to
analyse changes in heterogeneity and clonal composition during
drug treatment. This would allow new insights into these processes
and provide the basis to improve therapeutic outcomes based on
evolutionary theory and the specific targeting of distinct genomic
instability mechanisms.
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